
Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Full coverage of Patient-Centered Oncology Care, September 24-25, 2026, Nashville, Tennessee.

Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.

Oncology leaders discuss where AI delivers value, who bears liability, data readiness, and why humans must stay in the loop for clinical decisions.

Oncology leaders say clinical pathways must shift from static documents to tools that use patient-reported outcomes and AI to guide care.

Cancer care demand is constantly shifting, with panelists at PCOC 2026 debating the benefits of automation vs retaining live patient access.

Experts discuss financial toxicity, dosing, patient-reported outcomes, trial diversity, and survivorship gaps in community and academic oncology.

Leaders from Boehringer Ingelheim, Incyte, Pfizer, and Takeda told the audience at Patient-Centered Oncology Care® that artificial intelligence (AI) is compressing discovery timelines, but that gaps in testing, data, and community access still decide which patients benefit.

As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.

Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.

Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.

Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.

The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.

Community oncologists cited prior authorization as a barrier to care, even as AI adoption doubled in 2026, according to the Oncology Care Index.

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.